Potency, dissociation kinetics and reversibility of fentanyls and nitazenes by naloxone at the μ opioid receptor
Open accessAbstract
Background and Purpose Fentanyls and nitazenes are μ opioid receptor agonists responsible for a large number of opioid overdose deaths. Here, we compared the potency, dissociation kinetics and antagonism by naloxone at the μ receptor of several fentanyl and nitazene analogues and compared them to morphine and DAMGO. Experimental Approach In vitro assays of G protein activation and signalling and arrestin recruitment were performed. AtT20 cells expressing μ receptors were loaded with a membrane potential dye and changes in fluorescence used to determine agonist potency, dissociation kinetics and susceptibility to antagonism by naloxone. BRET experiments were undertaken in HEK293T cells expressing μ opioid receptors, to assess Gi protein activation and β-arrestin 2 recruitment. Key Results The rate of agonist dissociation from the μ receptor varied, with morphine, DAMGO, alfentanil and fentanyl dissociating rapidly whereas isotonitazene, etonitazene, ohmefentanyl and carfentanil dissociated slowly. Slowly dissociating agonists were more resistant to antagonism by naloxone. For carfentanil, the slow rate of dissociation was not due to G protein receptor kinase-mediated arrestin recruitment as its rate of dissociation was not affected by inhibition of GRKs with Compound 101. The in vitro relative potencies of fentanyls and nitazenes compared to morphine were much lower than that previously observed in in vivo experiments. Conclusions and Implications With fentanyls and nitazenes,…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many factors (e.g., receptor affinity, association/dissociation kinetics, etc.) are involved, which greatly impact agonist reversal by naloxone.
“Indeed, many factors (e.g., receptor affinity, association/dissociation kinetics, etc.) are involved, which greatly impact agonist reversal by naloxone (Alhosan et al., 2024; Bilel et al., 2022; Varshneya et al., 2022; Yassen et al., 2007).”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Alhosan et al., 2024
Cites
Community guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232 · see citing works
Irvine, M. A., Oller, D., Boggis, J., Bishop, B., Coombs, D., Wheeler, E., Doe-Simkins, M., Walley, A. Y., Marshall, B. D. L., Bratberg, J., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00304-2 · Cited by 127 · see citing works
De Luca, M. A., Tocco, G., Mostallino, R., Laus, A., Caria, F., Musa, A., Pintori, N., Ucha, M., Poza, C., Ambrosio, E., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109263 · Cited by 48 · see citing works
Nitazenes represent a growing threat to public health in Europe
Giraudon, I., Abel-Ollo, K., Vanaga-Arāja, D., Heudtlass, P., & Griffiths, P. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00024-0 · Cited by 40 · see citing works
Vandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Vandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107503 · Cited by 35 · see citing works
Vandeputte, M. M., Bilel, S., Tirri, M., Corli, G., Bassi, M., Layle, N. K., Fantinati, A., Walther, D., Iula, D. M., Baumann, M. H., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110113 · Cited by 19 · see citing works
- Authors
- Alhosan, N., Cavallo, D., Santiago, M., Kelly, E., & Henderson, G.
- Affiliations
- Princess Nourah bint Abdulrahman University (SA)
- University of Bristol (GB)
- Macquarie University (AU)
- Corresponding author
- Henderson, Graeme
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2024-06-05
- OpenAlex
- W4399917024
- Cited by
- 1
- References
- 5
- Citations by year
- 2024: 1
- Type
- posted content
- Language
- en
- Open access
- green
- dx.doi.org
- Licence
- cc-by-nc-nd
- Locations
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- fentanyl analogs, nitazenes, mu-opioid receptor, naloxone antagonism, opioid overdose, carfentanil, etonitazene, isotonitazene, alfentanil, morphine, DAMGO, arrestin recruitment, G protein activation, opioid potency, opioid overdose reversal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review